Table 1 Baseline clinical characteristics of participants

Age, years

68.61 ± 10.34

68.23 ± 11.37

0.446

Male, n (%)

479(50.42)

470(49.47)

0.680

APOA1, g/L

1.13 ± 0.26

1.23 ± 0.25

 < 0.001*

  Men, g/L

1.07 ± 0.25

1.15 ± 0.24

 < 0.001*

  Women, g/L

1.19 ± 0.27

1.30 ± 0.23

 < 0.001*

APOB, g/L

0.80 ± 0.38

0.99 ± 0.24

 < 0.001*

Lp (a), mg/L

23.55 ± 26.88

22.58 ± 24.40

0.410

TC, mmol/L

4.19 ± 1.10

5.02 ± 1.10

 < 0.001*

TG, mmol/L

1.24 ± 0.88

1.38 ± 1.25

0.004*

LDL-C, mmol/L

1.07 ± 0.30

1.20 ± 0.32

 < 0.001*

HDL-C, mmol/L

2.50 ± 0.90

2.96 ± 0.86

 < 0.001*

FBG, mmol/l

6.22 ± 2.11

6.23 ± 1.94

0.914

AST, U/L

25.30 ± 45.62

20.81 ± 10.87

0.003*

ALT, U/L

22.30 ± 27.37

20.35 ± 13.70

0.05

ALB, g/L

38.05 ± 4.64

40.09 ± 4.12

 < 0.001*

PAB, g/L

19.56 ± 5.94

22.25 ± 5.52

 < 0.001*

SCr, μmoI/L

78.46 ± 51.47

64.97 ± 26.65

 < 0.001*

SUA, mg/dL

5.89 ± 1.75

5.11 ± 1.37

 < 0.001*

Hypertension, n (%)

638(67.16)

324(34.11)

 < 0.001*

CHD, n (%)

840(88.42)

240(25.26)

 < 0.001*

Diabetes, n (%)

280(29.47)

157(16.53)

 < 0.001*

Statins, n (%)

627(66.00)

217(22.84)

 < 0.001*

CCBs, n (%)

343(36.11)

166(17.47)

 < 0.001*

β-blockers, n (%)

743(78.21)

159(16.74)

 < 0.001*

ACEI/ARB, n (%)

533(56.11)

139(14.63)

 < 0.001*